GeoVax to Conduct Investor and Partnering Meetings During 35th Annual J.P. Morgan Healthcare Conference
ATLANTA, GA–(Marketwired – Dec 7, 2016) – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is scheduling investor and corporate partnering meetings during the 35th Annual J.P. Morgan Healthcare Conference, to be held in San Francisco on January 9-12, 2017.
Senior management of GeoVax will be available for one-on-one meetings with investment professionals, fund managers, and business development representatives from the life sciences industry. The Company will provide an update on its vaccine development programs in the areas of HIV, Zika, hemorrhagic fevers, and hepatitis B, as well as its efforts in the immuno-oncology space.
Individuals interested in meeting with GeoVax are encouraged to reach out to the company through the scheduling platforms available through the conference websites for the Biotech Showcase (https://ebdgroup.knect365.com/biotech-showcase/), the Redefining Early Stage Investments (RESI) Conference (http://www.resiconference.com/), or through the partnering system hosted by the Biotechnology Innovation Organization (http://convention.bio.org/partner/). Non-conference meetings may also be scheduled by contacting Company management directly.
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. The Company’s development programs are focused on vaccines against HIV, Zika Virus, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa). GeoVax also recently began programs to evaluate the use of its MVA-VLP platform in cancer immunotherapy, and therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious virus-like particles (VLPs) from the cells of the very person receiving the vaccine, mimicking a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.
Certain statements in this document are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax’s vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax’s filings with the Securities and Exchange Commission including those set forth at “Risk Factors” in GeoVax’s Form 10-K.
Robert T. McNally, Ph.D.
GeoVax Labs, Inc.